No evidence for correlation between BRAFV600E mutational status of the tumor and clinical activity was found, suggesting that sorafenib is not an effective BRAF inhibitor or that additional sorafenib targets may play a role in the few patients who benefit from the drug. Here, BRAF is linked to neoplasm.